Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pharmacogenomics Market Revenue Growth On Track For A 10.2% CAGR Through 2030
The pharmacogenomics market has seen significant expansion in recent years. This market is set to increase from $9.84 billion in 2025 to $10.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion has been driven by factors such as increasing genomic research activities, the development of targeted therapies, a rising prevalence of chronic diseases, advancements in sequencing technologies, and the growing availability of genetic testing services.
The pharmacogenomics market is poised for substantial expansion over the next few years. It is projected to attain a value of $15.98 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.2%. The anticipated surge throughout the forecast period stems from escalating investments in precision medicine programs, the increasing uptake of AI-driven genomic analysis, the broadened application of pharmacogenomics in oncology and cardiology, a heightened focus on individualized drug development, and continuous advancements in bioinformatics platforms. Noteworthy trends for this period encompass a greater adoption of personalized medicine approaches, the rising utilization of genetic testing in drug selection, deeper integration of pharmacogenomic data into clinical workflows, the expansion of companion diagnostics, and an enhanced emphasis on precision therapeutics.
Get A Free Sample Report With In-Depth Market Insights:
Pharmacogenomics Market Growth Backed By Core Demand Fundamentals
The expansion of the pharmacogenomics market is anticipated to be driven by the rising incidence of chronic diseases. These are medical conditions that endure for prolonged durations, frequently throughout an individual’s life. The surge in chronic diseases can be attributed to the global population’s extended average lifespan, alongside the prevalent embrace of lifestyle risk factors like inactive habits, inadequate nutrition, and smoking. Pharmacogenomics provides a tailored treatment strategy for chronic ailments, considering unique genetic differences that influence how individuals react to medication. As an illustration, for the year 2025, the International Diabetes Federation, a Belgium-based health organization, noted that in 2024, around 589 million adults aged 20-79 were living with diabetes. This figure is forecasted to climb to 853 million by 2050, with over 4 in 5 diabetic adults residing in low and middle income countries. Consequently, the expanding prevalence of chronic diseases is fueling the development of the pharmacogenomics market.
Pharmacogenomics Market Segment Trends And Revenue Contributors
The pharmacogenomics market covered in this report is segmented –
1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
Subsegments:
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing
2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR
3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)
5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays
6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools
Pharmacogenomics Market Growth Trends Reshaping The Competitive Landscape
Key companies active in the pharmacogenomics market are increasingly prioritizing artificial intelligence (AI) driven systems that manage drug-drug interactions (DDIs) at the genomic level, thereby enhancing medication safety, lessening adverse reactions, and enabling highly tailored prescribing. AI-powered pharmacogenetics engines are advanced digital systems that utilize artificial intelligence to analyze an individual’s genetic profile and forecast their response to specific medications. For example, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, launched its Sirius model, an AI-powered pharmacogenetics engine that customizes drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius covers 730 drugs and 40 key pharmacogenes, allowing for much broader coverage than traditional pharmacogenomic solutions. This model is designed for use by hospital systems, diagnostic labs, and clinical research organizations, helping to mitigate adverse reactions and improve therapeutic outcomes.
Pharmacogenomics Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos
View The Full Pharmacogenomics Market Report:
Pharmacogenomics Market Geographic Spread And Regional Opportunities
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
